

**Table 1 : Profiles of patients enrolled in the first protocol with survivin-2B peptide alone**

<b>patient no.</b>	<b>age</b>	<b>sex</b>	<b>site of metastases</b>
<b>1</b>	<b>60</b>	<b>F</b>	<b>brain</b>
<b>2</b>	<b>42</b>	<b>F</b>	<b>lymph node, lung</b>
<b>3</b>	<b>50</b>	<b>F</b>	<b>lymph node, bone</b>
<b>4</b>	<b>34</b>	<b>F</b>	<b>lymph node, lung, liver, bone</b>
<b>5</b>	<b>71</b>	<b>F</b>	<b>local, lung</b>
<b>6</b>	<b>40</b>	<b>F</b>	<b>lymph node</b>
<b>7</b>	<b>70</b>	<b>F</b>	<b>local, brain, lung</b>
<b>8</b>	<b>46</b>	<b>F</b>	<b>lymph node, brain, lung</b>
<b>9</b>	<b>58</b>	<b>F</b>	<b>bone</b>
<b>10</b>	<b>51</b>	<b>F</b>	<b>lymph node</b>
<b>11</b>	<b>51</b>	<b>F</b>	<b>lymph node, lung, liver, bone</b>
<b>12</b>	<b>38</b>	<b>F</b>	<b>local, lymph node, brain, lung, bone</b>